文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

加纳阿克拉国家放疗中心宫颈癌体外放疗与近距离放疗经验

External Beam Radiation Therapy and Brachytherapy for Cervical Cancer: The Experience of the National Centre for Radiotherapy in Accra, Ghana.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-12-21

该研究回顾2006至2011年加纳阿克拉国家放疗中心接受根治性体外放疗联合近距离放疗的250例宫颈癌患者资料,中位随访2.4年,3年总生存率86%、局部区域复发率19%,常见晚期不良反应为阴道狭窄缩短(32%)。

要点

  • 根治性放化疗联合近距离放疗在撒哈拉以南非洲可获86%的3年总生存率。
  • 32%患者出现阴道狭窄缩短,为最常见晚期不良反应。
  • 近300例患者被建议根治性治疗但未返回开始治疗。

核心结论

  • 在加纳采用同步放化疗联合近距离放疗的宫颈癌患者中观察到良好的肿瘤学结局。

研究设计与样本

  • 回顾性队列研究,纳入2006至2011年在加纳阿克拉国家放疗中心接受根治性体外放疗联合近距离放疗的250例宫颈癌患者,排除未接受近距离放疗或姑息性治疗者。

主要发现

  • 中位诊断年龄55岁,FIGO分期IIB或更低者占63%。
  • A点中位剂量83 Gy(范围60-97.5 Gy),膀胱点中位剂量71 Gy,直肠点中位剂量65 Gy。
  • 69%患者接受≥4周期同步顺铂化疗,中位总治疗时间73天。
  • 中位随访2.4年,3年总生存率86%,局部区域复发率19%。
  • 最常见晚期不良反应为阴道狭窄缩短,发生率32%;另有近300例被建议根治性治疗但未返回开始治疗。

临床怎么用

  • 在资源有限地区,采用钴-60体外放疗联合低剂量率近距离放疗及同步顺铂化疗可作为宫颈癌根治性治疗方案。
  • 需关注阴道狭窄缩短等晚期不良反应并进行相应随访管理。
  • 应识别并干预患者从诊断到治疗及启动治疗前的脱失问题。

局限性

  • 回顾性研究设计,未常规进行分期CT扫描。
  • 部分患者从诊断到治疗存在延迟,生存分析从首次放疗日期开始计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Most women with cervical cancer in Sub-Saharan Africa present with locally advanced disease. These women require external beam radiation therapy and brachytherapy for curative treatment, but data on their outcomes remain sparse. We report data on treatment characteristics, follow-up, toxicity, and cancer outcomes in a large population of patients from the National Centre for Radiotherapy in Accra, Ghana. METHODS AND MATERIALS: The charts of patients treated from 2006 to 2011 were reviewed. Patients treated without brachytherapy or with palliative intent were excluded. Staging computed tomography scans were not routinely performed. Cobalt 60 external beam radiation therapy was followed by 2 low-dose-rate brachytherapy insertions. Concurrent weekly cisplatin was recommended. Because many patients experienced delays from diagnosis to treatment, we calculated overall survival and locoregional recurrence from the date of first radiation therapy to the event date-or last follow-up when no event recurred-using the Kaplan-Meier (product-limit) method. RESULTS: We included 250 patients with a median age at diagnosis of 55 years. The International Federation of Gynecology and Obstetrics stage was IIB or lower in 63% of patients. The median dose to point A was 83 Gy (range, 60-97.5 Gy). The median doses to the bladder and rectal points were 71 Gy and 65 Gy, respectively. Of the patients, 69% received ≥4 cycles of concurrent cisplatin. The median overall treatment time was 73 days. The median follow-up period was 2.4 years, with 3-year overall survival and locoregional recurrence rates of 86% and 19%, respectively. The most commonly reported late side effect was vaginal stenosis and shortening, occurring in 32% of patients. We also identified nearly 300 patients who were offered curative treatment but never returned to start treatment. CONCLUSIONS: We report promising outcomes in a population of women with cervical cancer treated with concurrent chemoradiation therapy and brachytherapy in Ghana. To our knowledge, this is the largest series of its kind, and it demonstrates what can be achieved with a well-established cancer program in Sub-Saharan Africa.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Vulpe H, Asamoah FA, Maganti M, et al. External Beam Radiation Therapy and Brachytherapy for Cervical Cancer: The Experience of the National Centre for Radiotherapy in Accra, Ghana. Int J Radiat Oncol Biol Phys. 2017. PMID: 29395628. doi:10.1016/j.ijrobp.2017.12.270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。